Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels.
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
In our Around the World in HTAs insight series we shed light on HTA successes and challenges around the world. In this edition, Sarin KC, Manit Sittimart, Chittawan Poonsiri, Yi Wang, and Simon Brassel take us to Thailand.
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Chris Sampson and Dan Ollendorf take us to the United States.
How Have HTA Agencies Evolved Their Methods Over Time?
29 April 2024
The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.
Kahneman’s legacy in health economics
4 April 2024
Daniel Kahneman (1934 – 2024) was a Nobel Prize-winning psychologist known for his pioneering work in behavioural economics.
The Future of NICE in a Changing HTA Landscape
11 March 2024
To commemorate NICE’s 25th anniversary, this OHE webinar explored the biggest challenges and opportunities for the NICE HTA program over the next 5-10 years.
Incorporating the Patient Voice in Health Technology Assessment
15 February 2024
The decision to adopt or not adopt a new healthcare technology, and the process by which this decision is made, affects patients, the health system, and wider society. In this Whitepaper, we suggest that the patient perspective is critical to making fully-informed decisions about the value of new technologies, but this perspective has not always been given the same weight as clinical and economic aspects in health technology assessment (HTA).